Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GPR3 | P46089 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30857515 | 0.81 | KDM4E (0.61) | KDM4EGPR3CYP1A2ALDH1A1NPC1 | |
| SCHEMBL28248628 | 0.81 | KDM4E (0.52) | KDM4EGPR3CYP1A2CYP2A6MAOA | |
| SCHEMBL27973182 | 0.79 | GPR3 (0.64) | KDM4EGPR3CYP1A2ALDH1A1HTT | |
| SCHEMBL9038627 | 0.79 | KDM4E (0.59) | KDM4EGPR3CYP1A2ALDH1A1HTT | |
| SCHEMBL28284564 | 0.78 | CYP1A2 (0.42) | CYP1A2PARP1ALDH1A1HTTNPC1 | |
| SCHEMBL10025808 | 0.78 | GPR3 (0.68) | KDM4EGPR3CYP1A2MAOAALDH1A1 | |
| SCHEMBL23003529 | 0.78 | KDM4E (0.57) | KDM4EGPR3CYP1A2ALDH1A1HTT | |
| SCHEMBL2569466 | 0.78 | KDM4E (0.57) | KDM4EGPR3CYP1A2ALDH1A1HTT | |
| SCHEMBL329543 | 0.78 | KDM4E (0.57) | KDM4EGPR3CYP1A2PARP1ALDH1A1 | |
| SCHEMBL329199 | 0.78 | KDM4E (0.57) | KDM4EGPR3CYP1A2CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108707111-A | A kind of green synthesis method of 6 (5H)-phenanthridines ketone derivatives | 浙江工业大学 | 2018-10-26 | — | — | CN | disclosed |
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2658858-A2 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| US-8258297-B2 | Transition metal complexes with bridged carbene ligands and use thereof in OLEDs | BASF SE (DE) | 2012-09-04 | — | — | US | disclosed |
| WO-2012092411-A2 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| EP-2205615-B1 | TRANSITION METAL COMPLEXES WITH BRIDGED CARBENE LIGANDS AND USE THEREOF IN OLEDS | BASF SE (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100264405-A1 | TRANSITION METAL COMPLEXES WITH BRIDGED CARBENE LIGANDS AND USE THEREOF IN OLEDS | BASF SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2205615-A1 | TRANSITION METAL COMPLEXES WITH BRIDGED CARBENE LIGANDS AND USE THEREOF IN OLEDS | BASF SE (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050281-A1 | TRANSITION METAL COMPLEXES WITH BRIDGED CARBENE LIGANDS AND USE THEREOF IN OLEDS | BASF SE (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| EP-0355575-A2 | Method of preventing polymer scale formation | Shin-Etsu Chemical Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, HPN, PRSS1 | KDM4E 2301/4885GPR3 2873/4885CYP1A2 564/4885 |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | KDM4E 3612/4885GPR3 1714/4885CYP1A2 1887/4885 |
| US-20100264405-A1 | TRANSITION METAL COMPLEXES WITH BRIDGED CARBENE LIGANDS AND USE THEREOF IN OLEDS | OCIAD1, OCIAD2, OPRD1 | KDM4E 4522/4885GPR3 1297/4885CYP1A2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.